```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 25   CA/CAPLUS - Russian Agency for Patents and Trademarks
                   (ROSPATENT) added to list of core patent offices covered
 NEWS  4  FEB 28   PATDPAFULL - New display fields provide for legal status
                   data from INPADOC
 NEWS  5  FEB 28   BABS - Current-awareness alerts (SDIs) available
 NEWS  6  FEB 28   MEDLINE/LMEDLINE reloaded
 NEWS  7  MAR 02   GBFULL: New full-text patent database on STN
 NEWS  8  MAR 03   REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  9  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  10 MAR 22   KOREAPAT now updated monthly; patent information enhanced
 NEWS  11 MAR 22   Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  12 MAR 22   PATDPASPC - New patent database available
 NEWS  13 MAR 22   REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  14 APR 04   EPFULL enhanced with additional patent information and new
                   fields
 NEWS  15 APR 04   EMBASE - Database reloaded and enhanced
 NEWS  16 APR 18   New CAS Information Use Policies available online
 NEWS  17 APR 25   Patent searching, including current-awareness alerts (SDIs),
                   based on application date in CA/CAplus and USPATFULL/USPAT2
                   may be affected by a change in filing date for U.S.
                   applications.
 NEWS  18 APR 28   Improved searching of U.S. Patent Classifications for
                   U.S. patent records in CA/CAplus

 NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:44:13 ON 17 MAY 2005

=> file medline, uspatful, dgene, embase, biosis, wpids
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

FULL ESTIMATED COST 0.42 0.42

FILE 'MEDLINE' ENTERED AT 18:45:04 ON 17 MAY 2005

FILE 'USPATFULL' ENTERED AT 18:45:04 ON 17 MAY 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 18:45:04 ON 17 MAY 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 18:45:04 ON 17 MAY 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 18:45:04 ON 17 MAY 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'WPIDS' ENTERED AT 18:45:04 ON 17 MAY 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

=> s gastric secretion inhibition and (decrease body weight or appeptite)
L1 0 GASTRIC SECRETION INHIBITION AND (DECREASE BODY WEIGHT OR APPEPT
ITE)

=> s gastric secretion and body weight
L2 1113 GASTRIC SECRETION AND BODY WEIGHT

=> s l2 and affects
L3 33 L2 AND AFFECTS

=> s l3 and decrease body weight
L4 0 L3 AND DECREASE BODY WEIGHT

=> d l3 ti abs ibib 1-20

L3 ANSWER 1 OF 33 MEDLINE on STN
TI Zinc deficiency: its role in **gastric secretion** and stress-induced gastric ulceration in rats.
AB The effects of zinc deficiency on **gastric secretion** and on cold-restraint stress-induced ulceration in rat stomachs have been studied. Administration of graded zinc deficient diets for 5 weeks significantly depressed the serum zinc concentration and decreased **body weight** gain in the rats. These diets significantly increased the gastric secretory volume, acid and pepsin. Zinc deficiency produced or aggravated the formation of glandular ulceration in the absence or presence of stress, respectively; it also decreased the mast cell count in the gastric glandular mucosa. It is concluded that zinc deficiency adversely **affects** the rats by reducing the **body weight** gain and producing ulceration which is probably mast cell-mediated. On the other hand, it increases gastric secretory functions.
ACCESSION NUMBER: 87204404 MEDLINE
DOCUMENT NUMBER: PubMed ID: 3575353
TITLE: Zinc deficiency: its role in **gastric secretion** and stress-induced gastric ulceration in rats.
AUTHOR: Cho C H; Fong L Y; Ma P C; Ogle C W
SOURCE: Pharmacology, biochemistry, and behavior, (1987 Feb) 26 (2) 293-7.
Journal code: 0367050. ISSN: 0091-3057.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198706
ENTRY DATE: Entered STN: 19900303
Last Updated on STN: 19970203
Entered Medline: 19870602

L3 ANSWER 2 OF 33 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2005:117724 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005100991	A1	20050512
APPLICATION INFO.:	US 2004-932104	A1	20040902 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-833118, filed on 12 Apr 2001, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15444

L3 ANSWER 3 OF 33 USPATFULL on STN
TI Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
AB The present invention is directed to, inter alia, pharmaceutical compositions comprising at least one proton pump inhibitor and at least one buffering agent. Compositions of the invention are useful in treating, inter alia, gastric acid related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:63640 USPATFULL
TITLE: Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
INVENTOR(S): Phillips, Jeffrey O., Ashland, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005054682	A1	20050310
APPLICATION INFO.:	US 2004-898135	A1	20040723 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-722184, filed on 25 Nov 2003, PENDING Continuation of Ser. No. US 2002-54350, filed on 19 Jan 2002, GRANTED, Pat. No. US 6699885 Continuation-in-part of Ser. No. US 2001-901942, filed on 9 Jul 2001, GRANTED, Pat. No. US 6645988 Continuation-in-part of Ser. No. US 2000-481207, filed on 11 Jan 2000, GRANTED, Pat. No. US 6489346 Continuation-in-part of Ser. No. US 1998-183422, filed on 30 Oct 1998, ABANDONED Continuation-in-part of Ser. No. US 1996-680376, filed on 15 Jul 1996, GRANTED, Pat. No. US 5840737

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-9608P	19960104 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MAYER, BROWN, ROWE & MAW LLP, 190 SOUTH LASALLE ST, CHICAGO, IL, 60603-3441
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 4983
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 33 USPATFULL on STN
TI Novel substituted benzimidazole dosage forms and method of using same
AB Disclosed herein are methods, kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:5065 USPATFULL
TITLE: Novel substituted benzimidazole dosage forms and method of using same
INVENTOR(S): Phillips, Jeffrey O., Ashland, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005004171	A1	20050106
APPLICATION INFO.:	US 2004-797374	A1	20040310 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2003-722184, filed on 25 Nov 2003, PENDING Continuation of Ser. No. US 2002-54350, filed on 19 Jan 2002, GRANTED, Pat. No. US 6699885 Continuation-in-part of Ser. No. US 2001-901942, filed on 9 Jul 2001, GRANTED, Pat. No. US 6645988 Continuation-in-part of Ser. No. US 2000-481207, filed on 11 Jan 2000, GRANTED, Pat. No. US 6489346 Continuation-in-part of Ser. No. US 1998-183422, filed on 30 Oct 1998, ABANDONED Continuation-in-part of Ser. No. US 1996-680376, filed on 15 Jul 1996, GRANTED, Pat. No. US 5840737

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-9608P	19960104 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MAYER, BROWN, ROWE & MAW LLP, 190 SOUTH LASALLE ST, CHICAGO, IL, 60603-3441
NUMBER OF CLAIMS: 150
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 5507
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 33 USPATFULL on STN
TI Use of a clostridial toxin to reduce appetite
AB Methods for reducing appetite by oral administration of a Clostridial toxin, such as a botulinum toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:320621 USPATFULL
TITLE: Use of a clostridial toxin to reduce appetite
INVENTOR(S): Voet, Martin A., San Juan Capistrano, CA, UNITED STATES
PATENT ASSIGNEE(S): Allergan, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004253274	A1	20041216
APPLICATION INFO.:	US 2003-459767	A1	20030611 (10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: STEPHEN DONOVAN, ALLERGAN, INC., 2525 Dupont Drive, T2-7H, Irvine, CA, 92612
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1949
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 33 USPATFULL on STN
TI Novel substituted benzimidazole dosage forms and method of using same
AB Disclosed herein are methods kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:221874 USPATFULL
TITLE: Novel substituted benzimidazole dosage forms and method of using same
INVENTOR(S): Phillips, Jeffrey O., Ashland, MO, UNITED STATES
PATENT ASSIGNEE(S): THE CURATORS OF THE UNIVERSITY OF MISSOURI, Columbia, MO, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171646	A1	20040902
APPLICATION INFO.:	US 2003-722184	A1	20031125 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-54350, filed on 19 Jan 2002, GRANTED, Pat. No. US 6699885 Continuation-in-part of Ser. No. US 2001-901942, filed on 9 Jul 2001, GRANTED, Pat. No. US 6645988 Continuation-in-part of Ser. No. US 2000-481207, filed on 11 Jan 2000, GRANTED, Pat. No. US 6489346 Continuation-in-part of Ser. No. US 1998-183422, filed on 30 Oct 1998, ABANDONED Continuation-in-part of Ser. No. US 1996-680376, filed on 15 Jul 1996, GRANTED, Pat. No. US 5840737

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-9608P	19960104 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MAYER, BROWN, ROWE & MAW LLP, 190 SOUTH LASALLE ST, CHICAGO, IL, 60603-3441
NUMBER OF CLAIMS: 150
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 5487
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 33 USPATFULL on STN
TI Opiate analogs selective for the delta -opioid receptor
AB Novel compounds which selectively bind to the δ-opioid receptor have been designed. These compounds have greater selectivity, improved water (blood) solubility, and enhanced therapeutic value as analgesics. Because agonists with selectivity for the δ-opioid receptor have shown promise in providing enhanced analgesis without the addictive properties, the compounds of the present invention are better than morphine, naltrindole (NTI), spiroindanyloxymorphone (SIOM), and other known μ-opioid receptor selectors as analgesics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:159426 USPATFULL
TITLE: Opiate analogs selective for the delta -opioid receptor
INVENTOR(S): Welsh, William J., Princeton, NJ, UNITED STATES
Yu, Seong Jae, Pennington, NJ, UNITED STATES
Nair, Anil, Oro Valley, AZ, UNITED STATES
PATENT ASSIGNEE(S): The Curators of the University of Missouri (U.S.

corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004122230	A1	20040624	
APPLICATION INFO.:	US 2003-665377	A1	20030918	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-411724P	20020918 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI L.L.P., 600 CONGRESS AVE., SUITE 2400, AUSTIN, TX, 78701
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 1490
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 33 USPATFULL on STN
TI Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
AB Pharmaceutical compositions and methods are described comprising at least one peptide YY compound and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of peptide YY to the blood plasma or central nervous system (CNS) tissue or fluid, for example, by yielding a peak concentration (C.sub.max) of the peptide YY in the blood plasma or CNS tissue or fluid of the subject that is 20% or greater compared to a peak concentration of the peptide YY in the blood plasma or CNS tissue or fluid of the subject following administration to the subject of a same concentration or dose of the peptide YY to the subject by subcutaneous injection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:150914 USPATFULL
TITLE: Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
INVENTOR(S): Quay, Steven C., Edmonds, WA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004115135	A1	20040617	
APPLICATION INFO.:	US 2002-322266	A1	20021217	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103
NUMBER OF CLAIMS: 94
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 9307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 33 USPATFULL on STN
TI Novel substituted benzimidazole dosage forms and method of using same
AB Disclosed herein are compositions and methods for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibitor (PPI) in a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:64377 USPATFULL
TITLE: Novel substituted benzimidazole dosage forms and method of using same

INVENTOR(S): Phillips, Jeffrey Owen, Ashland, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004048896	A1	20040311
APPLICATION INFO.:	US 2003-418410	A1	20030418 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-901942, filed on 9 Jul 2001, GRANTED, Pat. No. US 6645988 Continuation-in-part of Ser. No. US 2000-481207, filed on 11 Jan 2000, GRANTED, Pat. No. US 6489346 Continuation-in-part of Ser. No. US 1998-183422, filed on 30 Oct 1998, ABANDONED Continuation-in-part of Ser. No. US 1996-680376, filed on 15 Jul 1996, GRANTED, Pat. No. US 5840737

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-9608P	19960104 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MAYER, BROWN, ROWE & MAW, P.O. BOX 2828, CHICAGO, IL, 60690
NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 3917
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 33 USPATFULL on STN
TI Drosophila sequences
AB The present invention relates to Drosophila genes and methods for their use. The invention provides nucleotide sequences of Drosophila genes, amino acid sequences of the encoded proteins, and derivatives (e.g., fragments) and analogs thereof. The invention further relates to fragments (and derivatives and analogs thereof) of proteins which comprise one or more domains of a Drosophila protein. Antibodies to Drosophila proteins, and derivatives and analogs thereof, are also provided. Also provided herein are vectors and host cells comprising such nucleic acids. Methods of production of a Drosophila protein (e.g., by recombinant means), and derivatives and analogs thereof, are provided. Chimeric polypeptide molecules comprising polypeptides of the invention fused to heterologous polypeptide sequences are provided. Methods to identify the biological function of a Drosophila gene are provided, including various methods for the functional modification (e.g., overexpression, underexpression, mutation, knock-out) of one gene, or of two or more genes simultaneously. Methods to identify a Drosophila gene which modifies the function of, and/or functions in a downstream pathway from, another gene are provided. The invention further provides for use of Drosophila proteins as media additives or pesticides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:59931 USPATFULL
TITLE: Drosophila sequences
INVENTOR(S): Homburger, Sheila Akiko, San Francisco, CA, United States
Ebens, Jr., Allen James, San Francisco, CA, United States
Erickson, Catherine Sue, San Francisco, CA, United States
Francis-Lang, Helen Louise, San Francisco, CA, United States
Margolis, Jonathan Scott, San Francisco, CA, United States
Reddy, Bindu Priya, San Francisco, CA, United States
Ruddy, David Andrew, San Francisco, CA, United States
Buchman, Andrew Roy, San Francisco, CA, United States
PATENT ASSIGNEE(S): Exelixis, Inc., South San Francisco, CA, United States

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6703491	B1	20040309
APPLICATION INFO.:	US 1999-270767		19990317 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Horlick, Kenneth R.
ASSISTANT EXAMINER: Kim, Young
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 44 Drawing Figure(s); 44 Drawing Page(s)
LINE COUNT: 13127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 33 USPATFULL on STN
TI Methods for treating hyperactive gastric motility
AB This invention provides methods and pharmaceutical compositions for treating, inhibiting or preventing hyperactive gastric motility in a mammal utilizing agonists of KCNQ potassium channels, including KCNQ2, KCNQ3, KCNQ4 and KCNQ5 potassium channels, alone or in combination. The hyperactive gastric motility may be associated with maladies including, colitis, irritable bowel syndrome and Crohn's disease. Compounds useful in these methods include the 1,2,4-triamino-benzene derivatives described in U.S. Pat. Number 5,384,330 (Dieter et al.) and the substituted 3-phenyl oxindole compounds described in U.S. Pat. Number 5,565,483 (Hewawasam et al.).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:39407 USPATFULL
TITLE: Methods for treating hyperactive gastric motility
INVENTOR(S): Argentieri, Thomas M., Yardley, PA, UNITED STATES
PATENT ASSIGNEE(S): Wyeth, Madison, NJ, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004029949	A1	20040212
APPLICATION INFO.:	US 2003-635081	A1	20030806 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-114148, filed on 2 Apr 2002, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-281471P	20010404 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 629
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 33 USPATFULL on STN
TI Bioadhesive compositions and methods for topical administration of active agents
AB Bioadhesive compositions in a flexible, finite form for topical application to skin or mucous membranes comprising a composition which results from an admixture of at least one PVP polymer, at least one bioadhesive, optionally a pharmaceutically acceptable solvent suitable for use with an active agent, and methods of administering active agents to a subject, are disclosed. The bioadhesive composition can either include an active agent incorporated directly in the composition, or a separate source of an active agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:24403 USPATFULL
TITLE: Bioadhesive compositions and methods for topical administration of active agents
INVENTOR(S): Houze, David, Coconut Grove, FL, UNITED STATES
Mantelle, Juan, Miami, FL, UNITED STATES
Kanios, David, Miami, FL, UNITED STATES
PATENT ASSIGNEE(S): NOVEN PHARMACEUTICALS, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004018241	A1	20040129
APPLICATION INFO.:	US 2003-436126	A1	20030513 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-161312, filed on 28 Sep 1998, GRANTED, Pat. No. US 6562363

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1998-US20091	19980925
	US 1997-60155P	19970926 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 2739
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 33 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:312278 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 33 USPATFULL on STN

TI Novel substituted benzimidazole dosage forms and method of using same
AB Disclosed herein are methods, kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:271551 USPATFULL		
TITLE:	Novel substituted benzimidazole dosage forms and method of using same		
INVENTOR(S):	Phillips, Jeffrey O., Ashland, MO, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003191159	A1	20031009
	US 6699885	B2	20040302
APPLICATION INFO.:	US 2002-54350	A1	20020119 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-901942, filed on 9 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2000-481207, filed on 11 Jan 2000, GRANTED, Pat. No. US 6489346 Continuation-in-part of Ser. No. US 1998-183422, filed on 30 Oct 1998, ABANDONED Continuation-in-part of Ser. No. US 1996-680376, filed on 15 Jul 1996, GRANTED, Pat. No. US 5840737		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1996-9608P	19960104 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Joseph A. Mahoney, Mayer, Brown & Platt, P.O. Box 2828, Chicago, IL, 60690		
NUMBER OF CLAIMS:	150		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	5446		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 33 USPATFULL on STN
TI Compositions and methods for the transport of biologically active agents across cellular barriers
AB Disclosed herein are complexes and compounds that pass through cellular barriers to deliver compounds into, through and out of cells, and methods of producing and using such complexes and compounds. The complexes and compounds of the invention comprise a biologically active portion and a targeting element directed to a ligand that confers transcellular, transcytotic or paracellular transporting properties to an agent specifically bound to the ligand, with the proviso that the targeting element is not an antibody. Also disclosed are complexes and compounds that comprise two or more targeting elements directed to a ligand that confers transcellular, transcytotic or paracellular transporting properties to an agent specifically bound to the ligand. Preferred ligands include but are not limited to the stalk of pIgR, a pIgR domain, an amino acid sequence that is conserved among pIgR's from different animals, and one of several regions of pIgR defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:231611 USPATFULL		
TITLE:	Compositions and methods for the transport of biologically active agents across cellular barriers		
INVENTOR(S):	Houston, L. L., Del Mar, CA, UNITED STATES Sheridan, Philip J., San Diego, CA, UNITED STATES Hawley, Stephen B., San Diego, CA, UNITED STATES Glynn, Jacqueline M., San Diego, CA, UNITED STATES Chapin, Steven, San Diego, CA, UNITED STATES		
	NUMBER	KIND	DATE

PATENT INFORMATION: US 2003161809 A1 20030828
APPLICATION INFO.: US 2001-969748 A1 20011002 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-237929P	20001002 (60)
	US 2000-248478P	20001113 (60)
	US 2000-248819P	20001114 (60)
	US 2001-267601P	20010209 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278
NUMBER OF CLAIMS: 53
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 11304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 33 USPATFULL on STN
TI Methods for improving islet signaling in diabetes mellitus and for its prevention
AB The present invention discloses methods for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic β-cells, to cause differentiation of pancreatic epithelial cells into insulin producing β-cells, to improve muscle sensitivity to insulin and other weight control efforts by the chronic oral administration of a DP IV-inhibitor. The administration causes the active form of GLP-1 and other non-nutrient stimulated growth hormones to remain biologically active longer under physiological conditions. The extended presence of such hormones, in particular in the pancreatic tissue can also facilitate differentiation and regeneration of the β-cells already present that are in need of repair.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:173888 USPATFULL
TITLE: Methods for improving islet signaling in diabetes mellitus and for its prevention
INVENTOR(S): Demuth, Hans-Ulrich, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
Glund, Konrad, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
Pospisilik, J. Andrew, West Vancouver, CANADA
Kuehn-Wache, Kerstin, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119736	A1	20030626
	US 6890905	B2	20050510
APPLICATION INFO.:	US 2002-216349	A1	20020809 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-824622, filed on 2 Apr 2001, GRANTED, Pat. No. US 6500804
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROWN, RUDNICK, BERLACK & ISRAELS, LLP., BOX IP, 18TH FLOOR, ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 2337
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 33 USPATFULL on STN
TI Receptor-selective somatostatin analogs
AB Analogs of SRIF which are selective for SSTR3 in contrast to the other cloned SRIF receptors. These analogs are useful in determining the

tissue and cellular expression of the receptor SSTR3 and its biological role in the endocrine, exocrine and nervous system, as well as in regulating tumor growth. SRIF analog peptides, such as des-AA.sup.1,2,4,5,12,13[N.sup.βMeD-Agl.sup.8(2-naphthoyl)]-SRIF and counterparts incorporating D-Cys.sup.3 and/or Tyr.sup.7, inhibit the binding of a universal SRIF radioligand to the cloned human receptor SSTR3, but they do not bind with significant affinity to human SSTR1, SSTR2, SSTR4 or SSTR5. By incorporating an iodinated tyrosine in position-2 or in position-11 in these SSTR3-selective SRIF analogs, a labeled compound useful in drug-screening methods is provided. Because the N-terminus accommodates bulky moieties without loss of selectivity, a cytotoxin or a complexing agent to accept a radioactive nuclide may be present at the N-terminus. Alternatively, the binding affinity may be improved without detriment to the selectivity by adding a carbamoyl moiety at the N-terminus and/or replacing Phe.sup.11 with Aph or substituted Aph.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:162001 USPATFULL		
TITLE:	Receptor-selective somatostatin analogs		
INVENTOR(S):	Rivier, Jean E. F., La Jolla, CA, United States Reubi, Jean Claude, Berne, SWITZERLAND		
PATENT ASSIGNEE(S):	The Salk Institute for Biological Studies, San Diego, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6579967	B1	20030617
APPLICATION INFO.:	US 2000-607546		20000629 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-461651, filed on 14 Dec 1999, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kunz, Gary		
ASSISTANT EXAMINER:	Landsman, Robert S.		
LEGAL REPRESENTATIVE:	Fitch, Even, Tabin & Flannery		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	1356		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 18 OF 33 USPATFULL on STN

TI Bioadhesive compositions and methods for topical administration of active agents

AB Bioadhesive compositions in a flexible, finite form for topical application to skin or mucous membranes comprising a composition which results from an admixture of at least one PVP polymer, at least one bioadhesive, optionally a pharmaceutically acceptable solvent suitable for use with an active agent, and methods of administering active agents to a subject, are disclosed. The bioadhesive composition can either include an active agent incorporated directly in the composition, or a separate source of an active agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:129695 USPATFULL		
TITLE:	Bioadhesive compositions and methods for topical administration of active agents		
INVENTOR(S):	Mantelle, Juan, Miami, FL, United States Houze, David, Coconut Grove, FL, United States Kanios, David, Miami, FL, United States		
PATENT ASSIGNEE(S):	Noven Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6562363	B1	20030513
APPLICATION INFO.:	US 1998-161312		19980928 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-61155P	19970926 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Sheikh, Humera N.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2672
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 19 OF 33 USPATFULL on STN
TI Method for treating drug-induced constipation
AB Provided is a method for treating drug-induced constipation comprising a step of administering an effective amount of a 15-keto-prostaglaindin compound to a subject suffering from drug-induced constipation or a subject having a strong possibility of suffering from it. According to the present invention, a strong antagonistic action against drug-induced constipation can be obtained without substantially losing the main effect of the drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:106834 USPATFULL
TITLE: Method for treating drug-induced constipation
INVENTOR(S): Ueno, Ryuji, Montgomery, MD, UNITED STATES
PATENT ASSIGNEE(S): SUCAMPO, A.G. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003073746	A1	20030417	
APPLICATION INFO.:	US 2002-135397	A1	20020501	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-287720P	20010502 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, N.W., Washington, DC, 20037-3213
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 20 OF 33 USPATFULL on STN
TI Method for delivering benzidine prostaglandins by inhalation
AB A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:78038 USPATFULL
TITLE: Method for delivering benzidine prostaglandins by inhalation
INVENTOR(S): Cloutier, Gilles, Chapel Hill, NC, UNITED STATES
Crow, James, Chapel Hill, NC, UNITED STATES
Wade, Michael, Chapel Hill, NC, UNITED STATES
Parker, Richard E., Spring Hill, TN, UNITED STATES
Loyd, James E., Nashville, TN, UNITED STATES
PATENT ASSIGNEE(S): United Therapeutics Corporation (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2003053958	A1	20030320
	US 6756033	B2	20040629
APPLICATION INFO.:	US 2002-212149	A1	20020806 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-525471, filed on 15 Mar 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-124999P	19990318 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 764
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:44:13 ON 17 MAY 2005)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, BIOSIS, WPIDS' ENTERED AT 18:45:04 ON 17 MAY 2005

L1 0 S GASTRIC SECRETION INHIBITION AND (DECREASE BODY WEIGHT OR AP
L2 1113 S GASTRIC SECRETION AND BODY WEIGHT
L3 33 S L2 AND AFFECTS
L4 0 S L3 AND DECREASE BODY WEIGHT

=> s gastric secretion and appeptite
L5 0 GASTRIC SECRETION AND APPEPTITE

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 6596867 B2

L5: Entry 1 of 2 File: USPT Jul 22, 2003

US-PAT-NO: 6596867
DOCUMENT-IDENTIFIER: US 6596867 B2

TITLE: Tartrate salt of a substituted dipeptide as growth hormone secretagogue

DATE-ISSUED: July 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Carpino; Philip Albert	Groton	CT		
Dasilva-Jardine; Paul Andrew	Providence	RI		
Lefker; Bruce Allen	Gales Ferry	CT		
Murry; Jerry Anthony	Mystic	CT		

US-CL-CURRENT: 546/119; 530/333, 530/338

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

☐ 2. Document ID: US 6248717 B1

L5: Entry 2 of 2 File: USPT Jun 19, 2001

US-PAT-NO: 6248717
DOCUMENT-IDENTIFIER: US 6248717 B1

TITLE: Tartrate salt of a substituted dipeptide as growth hormone secretagogue

DATE-ISSUED: June 19, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Carpino; Philip Albert	Groton	CT		
Dasilva-Jardine; Paul Andrew	Providence	RI		
Lefker; Bruce Allen	Gales Ferry	CT		
Murry; Jerry Anthony	Mystic	CT		

US-CL-CURRENT: 514/19; 546/119

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents